New cancer drugs help upbeat AstraZeneca beat forecasts
Share:
(Reuters) - AstraZeneca forecast a second straight year of sales growth on Thursday, driven by cancer medicines and other new drugs as the British drugmaker recovers from losing major patents. AstraZeneca's push to turn around a slump in sales rides in large part on cancer treatments Imfinzi and Lynparza, as it looks to compete with Merck & Co's blockbuster Keytruda.The drugmaker's fourth quarter earnings showed oncology drug sales rose 61 percent year-on-year to $1.78 billion (1.38..